Tratamento em Qionghai (China)

Dr. Luan Tianyan, MD, is Head of Oncology. He was recruited to Hainan Province as a high-level talent. He is a visiting scholar at the Dana-Farber Cancer Institute (USA). He is also Director of the Clinical Research Office at Bozheng Hengda International Hospital. He serves on the standing committees of the Clinical Research Management Committee (Southern Oncology Clinical Research Association), the Immunotherapy Committee (Hainan Provincial Anti-Cancer Association), and the Hainan Province Drug Research Committee.

He has more than 20 years of oncology practice. He provides individualized, comprehensive care for gastrointestinal tumors, lung cancer, and breast cancer. He focuses on pain management, palliative care, and psychological support in advanced cancer. He also works on the clinical use and study of tumor immunotherapy, including personalized mRNA vaccines and CAR-T therapy. He develops and applies proprietary drugs and related technologies.

Dr. Li Yanwen is an early leader in functional neurosurgery in China. He is a founder of neurosurgical navigation in the country. He is a Visiting Professor at the University of Turin. His awards include the First Prize of the Shenzhen Science and Technology Progress Award and the Third Prize of the Guangdong Provincial Science and Technology Progress Award.

He specializes in stereotactic and functional neurosurgery. He has over 20 years of experience and has completed more than 10,000 surgical localization procedures for Parkinson’s disease, cerebral palsy, and epilepsy. He is skilled in stereotactic and navigation techniques. His focus includes precision treatment for hard-to-treat cerebral hemorrhage and traumatic brain injury, post-stroke paralysis, Parkinson’s disease, Alzheimer’s disease, and spinal cord injury. He also performs targeted surgery for autism. He studies stem-cell therapies for neurological and autoimmune diseases.

Dr. Chen Binglai is a biological immunology expert (MD). He holds a PhD in Medicine from Central South University, with a focus on genetics and integrated TCM and Western medicine. He completed postdoctoral training at New York University and the University of Bologna. He is a visiting professor at Zhongshan Hospital, Fudan University.

He is affiliated with the Shanghai Pujiang Talent Program and the Yangpu District 3310 Talent Program. He leads the innovation project “Cancer Treatment Based on Cell Culture Technology,” supported by the Pujiang Program.

He has years of oncology practice and extensive experience in treating malignant tumors. His work focuses on the clinical use and research of CAR-T, NK cell, and stem cell therapies. He uses the Lecheng pilot program to advance clinical translation in China and to offer personalized treatment plans.